ArticleCancers2022

Combination of Tipifarnib and Sunitinib Overcomes Renal Cell Carcinoma Resistance to Tyrosine Kinase Inhibitors via Tumor-Derived Exosome and T Cell Modulation.

Jacob W Greenberg et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.